Erin Valentine
About Erin Valentine
Erin Valentine is a Senior Scientist at Fulcrum Therapeutics, with a strong background in cell-based assay development and mechanism of action studies for rare diseases, oncology, and neurobiology. She has previously held positions at Merck and ORIG3N, and holds a Master of Science in Biotechnology and Biomedical Sciences from the University of Massachusetts Boston.
Current Role at Fulcrum Therapeutics
Erin Valentine serves as a Senior Scientist at Fulcrum Therapeutics, a position she has held since 2017. Based in Cambridge, Massachusetts, her work focuses on advancing scientific research in the field of therapeutics. She contributes her expertise in cell-based assay development and mechanism of action studies, particularly in areas related to rare diseases, oncology, and neurobiology.
Previous Experience at Merck
Erin Valentine worked at Merck for a total of eleven years, holding two roles. From 2005 to 2014, she served as a Research Biologist, where she gained extensive experience in target identification and validation. Following this, she transitioned to a Research Scientist role from 2014 to 2016 in Boston, where she continued to develop her skills in biomedical research.
Experience at ORIG3N
After her tenure at Merck, Erin Valentine joined ORIG3N as a Cell Scientist for a six-month period in 2016. During her time there, she applied her knowledge in cell-based assays to support the company's research initiatives in biotechnology.
Education and Expertise
Erin Valentine earned her Master of Science (M.S.) in Biotechnology and Biomedical Sciences from the University of Massachusetts Boston, completing her studies from 1998 to 2006. Her educational background has equipped her with a strong foundation in scientific principles, which she applies in her current research, particularly in the areas of rare diseases, oncology, and neurobiology.
Background in Cell-Based Assays
Erin Valentine has developed significant expertise in cell-based assay development throughout her career. Her work emphasizes mechanism of action studies, which are critical for understanding how potential therapies function at the cellular level. This expertise supports her contributions to translational research and lead optimization in drug development.